By Michael Smith, North American Correspondent, MedPage Today
Published: July 02, 2012
Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston
The multiple sclerosis medication fingolimod (Gilenya) led to “rapid and sustained” reductions in MRI-documented inflammatory lesion activity, researchers reported.
In a two-year randomized trial, the medication also slowed the rate of brain volume loss compared with placebo, according to Ernst-Wilhelm Radue, MD, of University Hospital Basel in Basel, Switzerland, and colleagues.
Changes in lesion volume over time also favored the medication rather than placebo, Radue and colleagues reported online in Archives of Neurology.
Combined with previously reported improvements in relapse rates and disability progression, the findings suggest that the drug — a sphingosine 1–phosphate receptor (S1PR) modulator — has a “positive impact on long-term disease evolution,” the researchers argued.
Information provided by: Cherie C. Binns RN BS MSCN
..
Please note that all comments are moderated.
So that you can be kept up to date with MS news
Click here to: REGISTER – for our weekly e-Newsletter
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
